Skip to content
Precision for Medicine
iStock-1421515036 (2)

Gene Expression Profiling of Biopsies

Gene expression profiling of tumor biopsies and liquid biopsies can provide insight into inflammation and overall immune status
Profiling of biopsies by gene expression can serve as a tool for screening tumors that may respond to treatments such as checkpoint inhibitors, for evaluating therapeutic efficacy, for illuminating mechanism of action, and for a range of other applications

Comprehensive and quantitative gene expression profiling

Precision offers gene expression profiling and transcriptomics assays to monitor immune status using next generation sequencing (NGS), NanoString, qPCR, and Droplet Digital PCR (ddPCR) technologies. For sample types and needs other than immune profiling of biopsies, Precision also offers a full suite of genomics applications.

Our services are designed to meet your project objectives, whether through pre-existing panels or a customized assay.

Illumina and Thermo Fisher NGS Sequencers

We use both Illumina and Thermo Fisher for next-gen sequencing. Also, RNA-seq studies are done using Illumina, including the AmpliSeq for Illumina Immune Response Panel.

NanoString nCounter®

For highly multiplexed, quantitative gene expression studies, we use the NanoString nCounter® platform. This system directly detects RNA, avoiding the potential for introduced bias with approaches that rely on PCR-based amplification.

We can use NanoString’s immuno-oncology and immunology panels or create a custom panel for your study.

QuantStudio 12K flex real-time PCR system

For cost-effective, multiplexed gene expression profiling of many samples in parallel, we offer analyses using OpenArray plates on the QuantStudio 12K Flex qPCR platform.

QX200 ddPCR

Digital PCR is appropriate when highly sensitive analyses and absolute quantification is needed. Precision utilizes the Bio-Rad QX200 ddPCR System.

Agena MassARRAY®

High-throughput solution for genotyping, somatic mutation detection, DNA methylation analysis, and gene expression regulation analysis. Precision for Medicine offers MassARRAY® assays either as an individual service or as part of a comprehensive therapeutic development package, which includes biomarker assays and clinical trials.

Precision also provides research-ready biospecimens

In addition to services, Precision has biospecimens ready for genomic analysis, as well as specimens pre-characterized via NGS.

Explore the Precision blog

Read our blog to gain more insights and discover work that Precision has supported.

Read: Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan

Clinical Trials

Expanding Clinical Trial Execution in Greater China: Beijing, Shanghai, Hong Kong & Taiwan

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=199521241215, hs_child_table_id=0, hs_updated_at=1774887081250, hs_published_at=1774960708819, description=An industry veteran with nearly three decades of experience in the clinical research industry and deep expertise in clinical operations and strategic leadership across both pharmaceutical and CRO environments. Held pivotal roles as Head of Clinical Operations for Greater China at Boehringer Ingelheim, leading trials in oncology, respiratory, stroke, and cardio-metabolic diseases and CEO of George Clinical, a global CRO with strong scientific capabilities in renal and oncology therapeutic areas. At Precision for Medicine, a leader for business strategy across the Asia Pacific region. Focused on driving regional growth, building strategic partnerships, and supporting excellence in portfolio delivery and client satisfaction. An acknowledged driver of precision-driven solutions that improve patient outcomes., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/James%20Cheong.png',altText='James Cheong',fileId=199519079710}, linkedin=https://www.linkedin.com/in/james-cheong-36a543a/, lastname=Cheong, hs_initial_published_at=1762885727645, hs_created_by_user_id=78347666, hs_created_at=1762885637470, hs_is_edited=false, hs_deleted_at=0, name=James, job=Senior Vice President, Asia Pacific, Clinical Solutions​, slug=james-cheong, hs_updated_by_user_id=65160865}, second={hs_id=199519203221, hs_child_table_id=0, hs_updated_at=1770145994248, hs_published_at=1774960708819, description=Highly accomplished global clinical operations executive with nearly three decades of experience providing strategic leadership, regional expansion, and operational excellence across Asia Pacific. Brings deep expertise across clinical development, project and portfolio operations, biometrics, regulatory affairs, safety and pharmacovigilance, quality management, and financial governance. Proven builder and scaler of high‑performing teams and start‑up operations in both regional and global environments. Recognized industry leader who actively contributes to advancing clinical research standards through advisory and governance roles across Asia., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Jing%20Ping%20Yeo.png',altText='Jing Ping Yeo',fileId=199530854290}, linkedin=https://www.linkedin.com/in/jing-ping-yeo/, lastname=Yeo, PhD , hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893091367, hs_is_edited=false, hs_deleted_at=0, name=Jing Ping, job=Vice President, Clinical Operations, Head of Asia Pacific​, slug=JingPing-Yeo, hs_updated_by_user_id=65160865}, third={hs_id=199528025104, hs_child_table_id=0, hs_updated_at=1774885968488, hs_published_at=1774960708819, description=With 20+ years of experience in the clinical trial industry, he has led project management, clinical operations, and business development teams. Prior to joining Precision, he served as the General Manager of Emerald (formerly George Clinical) China, and held project management and business development leadership roles at ICON, WuXi CDS, IQVIA, and KUNTUO. He has successfully led teams to complete more than 120 Phase I–IV clinical trials, many of which were MRCT studies across Asia‑Pacific, Australia, and the United States. He holds a Master’s degree in Urology from Peking University First Hospital., avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Zhenfei%20Yin.png',altText='Zhenfei Yin',fileId=199530854553}, lastname=Yin, hs_initial_published_at=1762893310168, hs_created_by_user_id=78347666, hs_created_at=1762893190542, hs_is_edited=false, hs_deleted_at=0, name=Zhenfei, job=China Country Head, Senior Director, Project Management​, slug=Zhenfei Yin, hs_updated_by_user_id=65160865}})
  • James C. avatar Jing Ping Y. avatar Zhenfei Y. avatar
  • James C.

    Jing Ping Y.

    Zhenfei Y.

Discover
Read: Strategic Management of Radiopharmaceutical Trial Complexity Strategic Management of Radiopharmaceutical Trial Complexity

Clinical Trials - Oncology

Strategic Management of Radiopharmaceutical Trial Complexity

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778843, hs_child_table_id=0, hs_updated_at=1774960706353, hs_published_at=1774960708819, description=Robert Bauer is an Executive Director of Operational Strategy at Precision with over 20 years of clinical trial operations experience from both the sponsor and CRO perspectives. He has led teams in the conduct of trials from Phase I through IV and has experience across a wide variety of trial designs. Bob has experience across many therapeutic areas some of which include rare diseases, oncology, depression, schizophrenia, and substance use disorders., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Bauer%20Square.webp',altText='Robert Bauer Square',fileId=165892429961}, linkedin=https://www.linkedin.com/in/robert-bauer-a78b704b, hs_name=, hs_path=, lastname=Bauer, hs_initial_published_at=1774887084379, hs_created_at=1709645745074, hs_is_edited=false, hs_deleted_at=0, name=Robert, position=Vice President, Operational Strategy, job=, slug=robert-bauer, email=, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Robert Bauer avatar

    Robert Bauer

Discover
Read: Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue

Oncology

Case Study: How Monitoring Caught a Silent PK Crisis in a CAR T Rescue

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=209924378674, hs_child_table_id=0, hs_updated_at=1774452297064, hs_published_at=1774960708819, description=Marlise Conrad is a Senior Clinical Trial Manager – Clinical Operations at Precision for Medicine, bringing more than 25 years of clinical research experience across CRA, start-up, and clinical trial management roles. She has over 17 years of experience as a Clinical Trial Manager, with prior experience as a CRA and global clinical lead, and a strong track record supporting multicenter Phase I–III clinical trials, including rescue studies. Marlise has extensive oncology experience across multiple solid tumor indications, including early-phase CAR‑T studies, and holds a Registered Nurse (RN) degree, which informs her patient-centered and detail-driven approach to trial execution., avatar=Image{width=5184,height=2920,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/marlise_conrad.jpg',altText='marlise_conrad',fileId=209132467611}, lastname=Conrad, hs_initial_published_at=1774452315067, hs_created_by_user_id=26433386, hs_created_at=1774452226032, hs_is_edited=false, hs_deleted_at=0, name=Marlise, job=Senior Clinical Trial Manager – Clinical Operations, slug=marlise-conrad, hs_updated_by_user_id=65160865}, second={}, third={}})
  • Marlise Conrad avatar

    Marlise Conrad

Discover